Screener
Theravance Biopharma TBPH Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Theravance Biopharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 9:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056760
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Operating lease liabilities | 10,752 | 10,945 |
| Income tax payable | 5,287 | 5,287 |
| Other accrued liabilities | 988 | 1,485 |
| Total current liabilities | 31,775 | 38,302 |
| Long-term operating lease liabilities | 29,752 | 31,758 |
| Future royalty payment contingency | 32,795 | 32,795 |
| Unrecognized tax benefits | 87,153 | 85,679 |
| Other long-term liabilities | 244 | 313 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Theravance Biopharma's total current liabilities?
- Theravance Biopharma (TBPH) reported total current liabilities of $31.78M in Q1 2026.
- How has Theravance Biopharma's total current liabilities changed year-over-year?
- Theravance Biopharma's total current liabilities increased by 0.9% year-over-year, from $31.5M to $31.78M.
- What is the long-term trend for Theravance Biopharma's total current liabilities?
- Over 5 years (2020 to 2025), Theravance Biopharma's total current liabilities has grown at a -20.9% compound annual growth rate (CAGR), from $123.57M to $38.3M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Theravance Biopharma's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude